#### Clinical and economic impact of pharmacists interventions related to antimicrobials in the hospital setting: A systematic review Clínica Leache L., Aquerreta I., Aldaz A., Idoate A., Ortega A. niversidad Abstract number: CP-193 de Navarra Pharmacy Service. Clínica Universidad de Navarra. **ATC code:** J01-Antibacterials Avenida Pío XII, 36. CP:31800. Pamplona (Spain) **Objective**

Summarize evidence regarding clinical and/or economic impact of Pharmacists' Interventions (PI) related to antimicrobials in the hospital setting, in order to identify those to prioritize. Methods

Search:

- PubMed + references in citations
- From Jan-2003 to Mar-2016
- Searching terms:

| Table 1. Inclusion and exclusion criteria for study selection |                            |                                      |  |  |  |  |  |
|---|----------------------------|--------------------------------------|--|--|--|--|--|
|   | Inclusion criteria         | Exclusion criteria                   |  |  |  |  |  |
| Design  | Comparative                | Non-comparative, reviews             |  |  |  |  |  |
| Language  | English, Spanish or French |                                      |  |  |  |  |  |
| Population  | Adults                     | Solely pediatric or cystic fibrosis  |  |  |  |  |  |
| Setting   | Hospital or emergencies    | Community or primary care            |  |  |  |  |  |
| Intervention  | PI only in antimicrobials  | Multidisciplinary team interventions |  |  |  |  |  |
| Comparison  | With PI vs. without PI     | Generalist vs. Infectious pharmacist |  |  |  |  |  |
| Outcomes  | Economical and/or clinical |                                      |  |  |  |  |  |

pharmacist\* or clinical pharmacist\* and antimicrobial\* or antibiotic\* or anti infective\*

#### Data collected from each selected paper:

- Author, year, country
- Patients characteristics
- Outcomes and type of outcome
- Design, setting (ward, hospital type)
- Sample size
  - Comparison tests
- PI and type of PI (SR= specific recommendations for specific patients, Policy= establishment of treatment policies, Education = sessions or education to health professionals)

**Risk of bias** of studies was assessed using Cochrane Collaboration's tool.

# Results

PubMed search

### Characteristics of studies




**Studies with significant impact** 

Num. of studies

15

Microbiol.



| ublished after 2010<br>uropean, 39% American<br>lulticenter<br>ocused on specific ward<br>Vith high risk of bias |                 |                | n=4 SR+Policy<br>n=3 SR+Education<br>n=1 SR+Policy+Education |      |      |                   |      |    |    | um. of |
|--|-----------------|----------------|--|------|------|-------------------|------|----|----|--------|
|  |                 |                | 0  |      |      | 5                 |      | 10 |    |        |
| Jncontrolled befor   | e-after study   | 61%            |  |      |      | De of P<br>cluded |      |    |    |        |
| 22% Control  | led befor-after | study          | dies   | 20   |      | 18                |      | 18 |    |        |
| Observational<br>based on databas  |                 | tudy           | er of studi  |      | 12   |                   | 14   |    | 14 |        |
| ndomized controll  | <br>ed trial    |                | Numbe  |      |      |                   |      |    |    | 2      |
| ntrolled trial   | Studi           | ies (%)        |  | Clin | ical | Treat             | ment | Со | st | Micı   |
| 20% 40   |                 | Type of outcom |  |      |      |                   |      |    |    |        |

n=23

Figure 1. Flow diagram

#### **Pharmacist Interventions:**

- Related to a specific patient
- Integrated in the health team
- Participating in rounds
- Incorporating guidelines, protocols, and education

#### Improved clinical outcomes Decreased:

- Post-operative infections
  - Antimicrobial adverse effects
- Length of stay
- Unplanned readmissions
- Mortality

Figure 2. Study designs

## Figure 4. Studies that evaluate each outcome and those with significant impact of PI

- ✓ Cost:Benefit (in 2 studies): 11-19 € avoided per 1€ invested
- ✓ No study found negative impact.
- ✓ 70-92% accepted recommendations
- Can't conclude that adding other type of strategies to SR would improve results.

Limitations: poor quality studies.

# **Conclusions**

- Pharmacists' interventions regarding antimicrobials have a positive impact on treatment related and clinical outcomes, and decrease hospital expenditures.
- Pharmacist in the health team giving advice related to specific patients has impact on key clinical outcomes

#### 40%

60%